Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UCB’s Next Allergy Partner Is Sanofi-Aventis

This article was originally published in The Pink Sheet Daily

Executive Summary

Xyzal, pending in the U.S. for allergic rhinitis treatment, could be a replacement for Allegra.

You may also be interested in...



UCB/Sanofi’s Xyzal Clears FDA As Once-Daily Antihistamine

Xyzal will be available for the fall allergy season after being approved for symptoms associated with seasonal and perennial allergic rhinitis.

UCB/Sanofi’s Xyzal Clears FDA As Once-Daily Antihistamine

Xyzal will be available for the fall allergy season after being approved for symptoms associated with seasonal and perennial allergic rhinitis.

UCB Receives “Complete Response” Letter For Cimzia

Firm says FDA seeks new information and clarification regarding the BLA.

Related Content

Topics

UsernamePublicRestriction

Register

PS064919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel